Enanta Pharmaceuticals (ENTA) Property, Plant & Equipment (Net) Growth (1y) (2013 - 2026)
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) Property, Plant & Equipment (Net) Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 24.71% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.77% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -99.85% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -5.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.70% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 10.87% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 19.14% |
| 10 | Enanta Pharmaceuticals | 409.30 Mn | 219.79 Mn | - | -12.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.77% |
| Mar 31, 2026 | -11.87% |
| Dec 31, 2025 | -8.19% |
| Sep 30, 2025 | 8.28% |
| Jun 30, 2025 | 46.17% |
| Mar 31, 2025 | 142.73% |
| Dec 31, 2024 | 208.34% |
| Sep 30, 2024 | 174.25% |
| Jun 30, 2024 | 108.52% |
| Mar 31, 2024 | 40.08% |
| Dec 31, 2023 | 39.59% |
| Sep 30, 2023 | 93.08% |
| Jun 30, 2023 | 161.86% |
| Mar 31, 2023 | 129.49% |
| Dec 31, 2022 | 59.74% |
| Sep 30, 2022 | 3.87% |
| Jun 30, 2022 | -30.62% |
| Mar 31, 2022 | -31.59% |
| Dec 31, 2021 | -30.21% |
| Sep 30, 2021 | -30.86% |